TCGA-E2-A1L6-01A-11R-A13Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.400
- PROTEIN_SECRETION+0.390
- UV_RESPONSE_DN+0.360
- ESTROGEN_RESPONSE_LATE+0.310
- TGF_BETA_SIGNALING+0.270
- FATTY_ACID_METABOLISM+0.230
- NOTCH_SIGNALING+0.230
- ANDROGEN_RESPONSE+0.220
- ANGIOGENESIS+0.190
- WNT_BETA_CATENIN_SIGNALING+0.190
Top 10 suppressed
- MYC_TARGETS_V2-0.590
- E2F_TARGETS-0.380
- G2M_CHECKPOINT-0.360
- INTERFERON_ALPHA_RESPONSE-0.330
- INTERFERON_GAMMA_RESPONSE-0.290
- MYC_TARGETS_V1-0.280
- ALLOGRAFT_REJECTION-0.270
- DNA_REPAIR-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- CHOLESTEROL_HOMEOSTASIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20020009.LumA | — | A | 0.852 |
| 2 | 20020070.LumA | — | A | 0.805 |
| 3 | TCGA-AR-A24W-01A-11R-A169-07 | — | A | 0.794 |
| 4 | TCGA-AC-A2FG-01A-11R-A17B-07 | — | A | 0.789 |
| 5 | TCGA-A2-A1G0-01A-11R-A13Q-07 | — | A | 0.782 |
| 6 | TCGA-A2-A1FZ-01A-51R-A14D-07 | — | A | 0.782 |
| 7 | 20020054.LumA | — | A | 0.779 |
| 8 | TCGA-D8-A1X8-01A-11R-A14M-07 | — | B | 0.779 |
| 9 | TCGA-A2-A1G6-01A-11R-A13Q-07 | — | A | 0.778 |
| 10 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.040 | Inavolisib | — uncovered |